---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-044823"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T05:02:49.213083+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma terminates Recordati license for neffy in EU/UK/MEA; reacquires rights for €3M upfront plus milestones

## Summary
- Terminated License and Supply Agreement with Recordati Ireland, effective immediately.
- Reacquired exclusive rights to neffy (epinephrine) for EU, UK, Middle East, Africa, Eurasia.
- Pays €3.0M upfront; Recordati eligible for up to €2.0M EMA milestone, €5.0M first commercial sale, up to €5.0M sales milestones.
- Total potential milestone payments to Recordati up to €12.0M.
- ARS regains control of development, manufacturing, regulatory, and commercialization in the territory.

## SEC filing metadata
- accession: 0001193125-23-044823
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312523044823/0001193125-23-044823-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312523044823/d469633d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-044823
- JSON: https://secwatch.observer/filing/0001193125-23-044823.json
- Plain text: https://secwatch.observer/filing/0001193125-23-044823.txt

## Key facts
- Material Agreements
  ARS Pharmaceuticals, Inc. entered into Termination Agreement with Recordati Ireland, LTD. valued at €3.0 million (effective 2023-02-22).
  - Action: entry
  - Agreement: supply
  - Counterparty: Recordati Ireland, LTD.
  - Value: €3.0 million
  - Effective: 2023-02-22
  source text: On February 22, 2023, ARS Pharmaceuticals, Inc. (the “Company”) entered into a Termination Agreement (the “Termination Agreement”) with Recordati Ireland, LTD. (“Recordati”), pursuant to which, among other things, the Company and Recordati agreed to terminate that certain License and Supply Agreement, dated September 21, 2020, by and between the Company and Recordati (the “License and Supply Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312523044823/0001193125-23-044823-index.htm
- Material Agreements
  ARS Pharmaceuticals, Inc. terminated License and Supply Agreement with Recordati Ireland, LTD. (effective 2023-02-22).
  - Action: termination
  - Agreement: license
  - Counterparty: Recordati Ireland, LTD.
  - Effective: 2023-02-22
  source text: On February 22, 2023, the Company entered into the Termination Agreement with Recordati, pursuant to which, among other things, the Company and Recordati agreed to terminate the License and Supply Agreement, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312523044823/0001193125-23-044823-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.